Suppr超能文献

新生儿应使用哪种维生素K制剂?

Which vitamin K preparation for the newborn?

出版信息

Drug Ther Bull. 1998 Mar;36(3):17-9. doi: 10.1136/dtb.1998.36317.

Abstract

Newborn babies are at risk of bleeding as a result of vitamin K deficiency. Vitamin K supplements given at birth reduce this risk but it is not clear which preparation should be used. Until the early 1990s, it was standard practice to give vitamin K as a single intramuscular injection at birth (Konakion Ampoules 1 mg/0.5 ml-Roche). Studies published in 1990 and 1992 suggested a possible link between intramuscular vitamin K injection and childhood cancers, particularly leukaemias. Our response was to recommend that vitamin K injection be given orally (not then a licensed route) until a licensed oral preparation became available. Such a preparation is now marketed as Konakion MM Paediatric (Roche). In addition, the suggested association between intramuscular vitamin K and cancer has been further investigated. In this article, we update our advice.

摘要

新生儿因维生素K缺乏有出血风险。出生时给予维生素K补充剂可降低此风险,但尚不清楚应使用哪种制剂。直到20世纪90年代初,在出生时给予单次肌内注射维生素K(科纳康安瓿1毫克/0.5毫升 - 罗氏公司)是标准做法。1990年和1992年发表的研究表明,肌内注射维生素K与儿童癌症,尤其是白血病之间可能存在联系。我们的应对措施是建议口服维生素K注射剂(当时并非许可途径),直到有许可的口服制剂可用。现在有一种这样的制剂作为科纳康MM儿科版(罗氏公司)上市。此外,已对肌内注射维生素K与癌症之间的关联建议进行了进一步调查。在本文中,我们更新了我们的建议。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验